Ignite Creation Date:
2025-12-24 @ 6:33 PM
Ignite Modification Date:
2026-04-09 @ 6:57 AM
Study NCT ID:
NCT05431257
Status:
RECRUITING
Last Update Posted:
2022-06-24
First Post:
2022-06-01
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Azacitidine in Combination With Low Dose Intensity Venetoclax in Patients With AML Incl. Explorative AML Profiling
Sponsor:
Rigshospitalet, Denmark
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
H-21030117
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None